DOCSLIB.ORG

Annex II Marketable but Non-Prescribable Narcotic Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annex II Marketable but Non-Prescribable Narcotic Drugs Annex II (ad section 1 subsection 1) (marketable but non-prescribable narcotic drugs) (The original text has been published in the Federal Law Gazette (Bundesgesetzblatt - BGBl.) I 2001, 1187 - 1189) Column 1 contains the International Nonproprietary Names (INN) of the World Health Organisation. In naming a substance, the INN has priority over all other names. Column 2 contains other non-protected names of substances (short or trivial names). If there is no INN for a substance, the name printed in bold in this column may be used to name the substance unambiguously. All other names not printed in bold are not unambiguous in scientific terms. For this reason, they have to be used together with the name in column 3. Column 3 contains the chemical names of substances pursuant to the nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no name is listed in column 1 or 2, the name listed in column 3 is to be used. INN other non-protected or trivial names chemical names (IUPAC) Amphetaminil - (Phenyl)[ (1-phenylpropan-2-yl) amino] acetonitril - Benzylpiperazine (BZP) 1-Benzylpiperazin - Butobarbital 5-Butyl-5-ethylpyrimidin-2, 4, 6 (1H,3H, 5H)-trion - meta-Chlorphenylpiperazine (m-CPP) 1- (3-Chlorphenyl)piperazin Amineptine - 7-(10,11-Dihydro-5H-dibenzo(a,d)(7)annulen-5- ylamino)heptansäure Aminorex - 5-Phenyl-4, 5-dihydro-1, 3-oxazol-2-ylazan Butalbital - 5-Allyl-5-isobutylbarbitursäure - CP 47,497 5-(1,1-Dimethylheptyl)-2-[ (1RS,3SR)-3- (cis-3-[ 4- (1, 1-Dimethyl-heptyl) -2-hydroxyphenyl] -cyclohexanol) hydroxycyclohexyl] –phenol - CP 47,497-C6-Homolog 5-(1,1-Dimethylhexyl)-2-[ (1RS,3SR)-3- (cis-3-[ 4- (1, 1-Dimethyl-hexyl) -2-hydroxyphenyl] -cyclohexanol) hydroxycyclohexyl] -phenol - CP 47,497-C8-Homolog 5-(1,1-Dimethyloctyl)-2-[ (1RS,3SR)-3- (cis-3-[ 4- (1, 1-Dimethyl-octyl) -2-hydroxyphenyl] -cyclohexanol) hydroxycyclohexyl] -phenol - CP 47,497-C9-Homolog 5-(1,1-Dimethylnonyl)-2-[ (1RS,3SR)- (cis-3-[ 4- (1, 1-Dimethyl-nonyl) -2-hydroxyphenyl] -cyclohexanol) 3-hydroxycyclohexyl] -phenol Cetobemidone Ketobemidone 1- (4- (3-Hydroxyphenyl) -1-methyl-4- piperidyl) propan-1-on - d-Cocaine Methyl(3ß-(benzoyloxy)tropan- 2alpha-carboxylat - Dextromethadone (S)-6-Dimethylamino-4,4- diphenylheptan-3-on Cyclobarbital - 5-(Cyclohex-1-en-1-yl) -5-ethylpyrimidin-2, 4, 6 (1H, 3H, 5H) –trion Dextromoramide - (S)-3-Methyl-4-morpholino-2,2- diphenyl-1-(pyrrolidin-1-yl)butan-1- on Dextropropoxyphene - ((2S, 3R) -4-Dimethylamino-3-methyl-1, 2-diphenylbutan-2-yl)propionat - Diamorphine [ (5R,6S)-4,5-Epoxy-17- methylmorphin-7-en-3, 6-diyl] diacetat – if intended for the production of preparations for medical purposes Difenoxin - 1-(3-Cyan-3,3-diphenylpropyl)- 4 - phenylpiperidin-4-carbonsäure except in preparations which, without another substance from annexes I to III, contain up to 0.5 mg of Difenoxin, calculated as a base, per portion and, in relation to this quantity, at least 5 per cent of atropine sulphate -- - Dihydromorphine 4, 5alpha-Epoxy-17-methyl-morphinan-3, 6alpha- diol - Dihydrothebaine 4,5alpha-Epoxy-3,6-dimethoxy-17- methylmorphin-6-en Diphenoxylate - Ethyl(1-(3-cyan-3,3-diphenyl-propyl)-4- phenylpiperidin-4-carboxylat) - except in preparations which, without another substance from annexes I to III, contain up to 0.25 per cent of Diphenoxylate, calculated as a base, or up to 2.5 mg per portion and, in relation to these quantities, at least 1 per cent of atropine sulphate - - Ecgonine 3ß-Hydroxytropan-2ß-carbonsäure - Erythroxylum coca (plants and parts of plants belonging to the erythroxylum coca - species - including the bolivianum, spruceanum and novogranatense varieties) Ethchlorvynol - 1-Chlor-3-ethylpent-1-en-4-in-3-ol Ethinamate - (1-Ethinylcyclohexyl)carbamat 3-O-Ethylmorphine (Ethylmorphine) 4,5alpha-Epoxy-3-ethoxy-17-methylmorphin-7- en-6alpha-ol except in preparations which, without another substance from annexes I to III, contain up to 2.5 per cent of Ethylmorphine or up to 100 mg per portion, calculated as a base- Etilamfetamin N-Ethylamphetamine (Ethyl) (1-phenylpropan-2-yl)azan Fencamfamine - N-Ethyl-3-phenylbicyclo[ 2.2.1]heptan-2-amin Glutethimide - 3-Ethyl-3-phenylpiperidin-2, 6-dion - Isocodeine 4,5alpha-Epoxy-3-methoxy-17-methylmorphin-7- en-6ß-ol Isomethadone - 6-Dimethylamino-5-methyl-4, 4-diphenylhexan-3 –on - JWH-018 (Naphthalin-1-yl) (1-pentyl-1H-indol-3-yl)methanon (1-Pentyl-3-(1-naphthoyl)indol) - JWH-019 (Naphthalin-1-yl) (1-hexyl-1H- indol-3-yl)methanon (1-Hexyl-3- (1-naphthoyl)indol) - JWH-073 (Naphthalin-1-yl) (1-butyl-1H-indol-3-yl)methanon (1-Butyl-3- (1-naphthoyl) indol) Levamfetamin Levamphetamine (R) -1-Phenylpropan-2-ylazan - Levmetamfetamine (R)-(Methyl) (1-phenylpropan-2-yl)azan (Levometamfetamine) Levomoramide - (R)-3-Methyl-4-morpholino-2,2-diphenyl-1- (pyrrolidin-1-yl)butan-1-on Levorphanol - (9R,13R,14R)-17-Methylmorphinan-3-ol 17-methylmorphinan-3-ol Mazindol - 5-(4-Chlorphenyl)-2,5-dihydro-3H-imidazol[2,1-a] isoindol-5-ol Mefenorex - 3-Chlor-N-(1-phenylpropan-2-yl)propan-1-amin Meprobamate - (2-Methyl-2-propylpropan-1, 3-diyl)dicarbamat Mesocarb - (Phenylcarbamoyl) (3-(1-phenylpropan-2-yl) -1,2,3- oxadiazol-3-ium-5-yl) azanid Metamfetamin Methamphetamine (2S) -N-Methyl-1-phenylpropan-2-amin Methaqualon - 2-Methyl-3- (2-methylphenyl)chinazolin-4 (3H) –on Methyprylon - 3, 3-Diethyl-5-methylpiperidin-2, 4-dion - Oripavine 4, 5alpha-Epoxy-6-methoxy-17-methylmorphina-6, 8-dien-3-ol (RS) -Metamfetamin Methamphetamine racemate (RS)-(Methyl)(1-phenylpropan-2-yl)azan - methadone intermediate 4-Dimethylamino-2, 2-diphenylpentannitril (Premethadone) (RS;SR)-Methylphenidat - Methyl((RS;SR) (phenyl) (2-piperidyl) acetat) - Concentrate of poppy straw (the material arising when plants and parts of plants - of the Papaver somniferum species are subjected to a process for the concentration of the alkaloids) - Moramide intermediate 3-Methyl-4-morpholino-2, 2-diphenylbutansäure (Premoramide) Nicocodine 6-Nicotinoylcodeine (4, 5alpha-Epoxy-3-methoxy-17-methylmorphin-7- en- 6alpha-yl) nicotinat Nicodicodin 6-Nicotinoyldihydrocodeine (4,5alpha-Epoxy-3-methoxy-17- methylmorphinan-6alpha-yl)nicotinat - Papaver bracteatum - (plants and parts of plants,except seeds, belonging to the Papaver bracteatum species) - except for decorative purposes - - - Pethidine intermediate A 1-Methyl-4-phenylpiperidin-4-carbonitril (Prepethidin) - Pethidine intermediate B Ethyl(4-phenylpiperidin-4-carboxylat) (Norpethidine) - Pethidine intermediate C 1-Methyl-4-phenylpiperidin-4-carbonsäure (Pethidinic Acid) Oxymorphone - 14-Hydroxydihydromorphinon 4, 5a-Epoxy-3, 14- dihydroxy-17-methylmorphinan- 6-on Phendimetrazine - (2S,3S) -3,4-Dimethyl-2-phenylmorpholin Phenmetrazine - 3 -Methyl-2-phenylmorpholin Pholcodine Morpholinylethylmorphine 4, 5alpha-Epoxy-17-methyl-3-(2- morpholinoethoxy)morphin-7- en- 6alpha-ol - except in preparations which, without another substance from annexes I to III, contain, as solutions, up to 0.15 per cent of pholcodine, but not more than 150 mg per package unit or up to 20 mg per dosage unit, calculated as a base - Propiram - N- (1-Piperidinopropan-2-yl)-N- (2- pyridyl)propanamid Pyrovalerone - 2- (Pyrrolidin-1-yl) -1- (p-tolyl)pentan-1-on Racemoramide - (RS)-3-Methyl-4-morpholino-2,2-diphenyl-1- (pyrrolidin-1-yl)butan-1-on Racemorphan - (9RS,13RS,14RS)-17-Methyl-morphinan-3-ol - delta9-Tetrahydro-cannabinol 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro- (delta9-THC) 6H-benzo(c)chromen-1-ol - Tetrahydrothebaine 4,5alpha-Epoxy-3, 6-dimethoxy-17 - methylmorphinan Secbutabarbital Butabarbital 5- (Butan-2-yl)-5-ethylpyrimidin-2,4,6 (1H, 3H, 5H) –trion Thebacon Acetyldihydrocodeinone (4, 5alpha-Epoxy-3-methoxy-17-methylmorphin- 6- en-6-yl) acetat - Thebaine 4,5alpha-Epoxy-3,6-dimethoxy-1 7-methylmorphina- 6,8-dien cis-Tilidin - Ethyl((1RS,2RS)-2-dimethyl-amino-1- phenylcyclohex-3-encarboxylat) Vinylbital - 5-Ethenyl-5- (pentan-2-yl)pyrimidin-2, 4, 6 (1H, 3H, 5H) – trion Zipeprol - 1-Methoxy-3-(4-(2-methoxy-2- phenylethyl)piperazin-1-yl) - 1-phenylpropan-2 –ol - the esters, ethers and molecular compounds of the substances listed in this annex, as well as the esters and ethers of the substances listed in annex III, with the exception of gamma-hydroxybutyric acid (GHB), if they do not appear in another annex and whenever the existence of such esters, ethers and molecular compounds is possible; - the salts of the substances listed in this annex, whenever the existence of such salts is possible, as well as the salts and molecular compounds of the substances listed in annex III, whenever the existence of such salts and molecular compounds is possible and they are not used for medical, dental or veterinary purposes; - the preparations of the substances listed in this annex unless a) they are exclusively intended for diagnostic or analytical purposes, without being used on or in the human or animal body, and their content of one or more narcotics, in the case of lyophilizates and mixtures of substances intended for similar use in ready-made solutions, does not exceed 0.01 per cent in each case or the substances in the preparations are isotope-modified or b) they are specifically exempted. .
Load more

Recommended publications
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist D- Methadone for Treatment of Psychiatric Symptoms
    January 9, 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d- Methadone for Treatment of Psychiatric Symptoms Patent significantly expands Relmada intellectual property protection and positions company to target global commercial opportunities for wide range of psychiatric disorders. NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the European Patent Office has issued a notice of allowance for patent application number 13773543.7 for "D-methadone for the treatment of psychiatric symptoms." The patent provides broad coverage in Europe for d- Methadone (dextromethadone, REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a range of psychological and psychiatric disorders including depression, anxiety, fatigue and mood instability. "The allowance of this key patent significantly strengthens our IP position and the global commercial opportunities in our d-Methadone program," said Sergio Traversa, CEO of Relmada Therapeutics. "We look forward to advancing our current development programs and to working to identify potential new areas of unmet need where d-Methadone can deliver benefits to patients in the years ahead." The NMDA receptor is a predominant molecular device for controlling synaptic plasticity and memory function and affects the transfer of electrical signals between neurons in the brain and in the spinal column. Based on their mechanism of action, a range of NMDA receptor antagonists (chemicals that deactivate the NMDA receptor) such as d-Methadone are under consideration as potential therapeutic agents for the treatment of many CNS conditions including some psychiatric disorders.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • Relmada Announces FDA Fast Track Designation for D-Methadone for Adjunctive Treatment of Major Depressive Disorder
    April 13, 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder NEW YORK, April 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the company's novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose, according to the FDA, is to get important new drugs to the patient earlier. Drugs that receive Fast Track designation may be eligible for more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "Treatment of depression continues to be a significant challenge in healthcare affecting millions of patients around the world," said Richard Mangano, Ph.D., chief scientific officer of Relmada. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of care. We look forward to working with the FDA to advance the development program for d-Methadone and an expedited regulatory process." Relmada is planning to advance the development program for REL-1017 to a phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Pjp3'2001.Vp:Corelventura
    Copyright © 2001 by Institute of Pharmacology Polish Journal of Pharmacology Polish Academy of Sciences Pol. J. Pharmacol., 2001, 53, 253261 ISSN 1230-6002 INFLUENCE OF DOXEPIN USED IN PREEMPTIVE ANALGESIA ON THE NOCICEPTION IN THE PERIOPERATIVE PERIOD. EXPERIMENTAL AND CLINICAL STUDY Jerzy Wordliczek, Marcin Banach, Magdalena Dorazil, Barbara Przew³ocka*,# Department of Anaesthesiology and Intensive Care, 1st Chair of General Surgery of Collegium Medicum, Jagiellonian University, Kopernika 17, PL 31-501 Kraków, Poland, *Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Influence of doxepin used in preemptive analgesia on the nociception in the perioperative period. Experimental and clinical study. J. WORDLI- CZEK, M. BANACH, M. DORAZIL, B. PRZEW£OCKA. Pol. J. Pharma- col., 2001, 53, 253–261. The aim of the present research was to assess in experimental and clini- cal study the influence of doxepin administered intraperitoneally (ip) as pre- emptive analgesia on the nociception in the perioperative period. The pain thresholds for mechanical stimuli were measured in rats. The objective of clinical investigation was to assess the influence of preemptive administra- tion of doxepin on postoperative pain intensity, analgesic requirement in the early postoperative period as well as an assessment of the quality of postope- rative analgesia by the patient. Doxepin injected ip (3–30 mg/kg) dose-dependently increased the pain threshold for mechanical stimuli measured in paw pressure test in rats. Do- xepin injected 30 min before formalin significantly increased the nociceptive threshold in the paw pressure test. In contrast, doxepin injected 240 min before formalin or 10 min after formalin did not change the nociceptive threshold.
    [Show full text]
  • "Official Gazette of RM", No. 28/04 and 37/07), the Government of the Republic of Montenegro, at Its Meeting Held on ______2007, Enacted This
    In accordance with Article 6 paragraph 3 of the FT Law ("Official Gazette of RM", No. 28/04 and 37/07), the Government of the Republic of Montenegro, at its meeting held on ____________ 2007, enacted this DECISION ON CONTROL LIST FOR EXPORT, IMPORT AND TRANSIT OF GOODS Article 1 The goods that are being exported, imported and goods in transit procedure, shall be classified into the forms of export, import and transit, specifically: free export, import and transit and export, import and transit based on a license. The goods referred to in paragraph 1 of this Article were identified in the Control List for Export, Import and Transit of Goods that has been printed together with this Decision and constitutes an integral part hereof (Exhibit 1). Article 2 In the Control List, the goods for which export, import and transit is based on a license, were designated by the abbreviation: “D”, and automatic license were designated by abbreviation “AD”. The goods for which export, import and transit is based on a license designated by the abbreviation “D” and specific number, license is issued by following state authorities: - D1: the goods for which export, import and transit is based on a license issued by the state authority competent for protection of human health - D2: the goods for which export, import and transit is based on a license issued by the state authority competent for animal and plant health protection, if goods are imported, exported or in transit for veterinary or phyto-sanitary purposes - D3: the goods for which export, import and transit is based on a license issued by the state authority competent for environment protection - D4: the goods for which export, import and transit is based on a license issued by the state authority competent for culture.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]